Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.420
-0.030 (-2.07%)
At close: Apr 28, 2026, 4:00 PM EDT
1.490
+0.070 (4.93%)
After-hours: Apr 28, 2026, 5:57 PM EDT
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$709,334
Profits / Employee
-$2,432,724
Market Cap
23.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| Jasper Therapeutics | 22 |
| OSR Holdings | 22 |
| NewcelX | 15 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 10 |
MRKR News
- 5 weeks ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire
- 2 months ago - Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - GlobeNewsWire
- 6 months ago - Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting - GlobeNewsWire
- 7 months ago - Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - GlobeNewsWire